Naibo Hu

674 total citations
31 papers, 418 citations indexed

About

Naibo Hu is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Naibo Hu has authored 31 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 20 papers in Genetics and 10 papers in Molecular Biology. Recurrent topics in Naibo Hu's work include Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Naibo Hu is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Naibo Hu collaborates with scholars based in China, United Kingdom and United States. Naibo Hu's co-authors include L.C. Zhang, Lijuan Pan, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Robert Peter Gale, Liwei Fang, Bing Li, Yue Zhang and Gang Huang and has published in prestigious journals such as Blood, Journal of Materials Processing Technology and British Journal of Haematology.

In The Last Decade

Naibo Hu

29 papers receiving 408 citations

Peers

Naibo Hu

HEMAT

GENET

Arijit Nag India

Patricia Rubio Spain

Ray Tanaka Japan

Ina Laura Pieper United Kingdom

Lanting Liu China

S S Kelley United States

Paul A. Sanders United Kingdom

Yuan Feng China

Bernd Ishaque Germany

Chen Yao Su Taiwan

Arijit Nag India

Naibo Hu

52 ×0.2

HEMAT

43 ×0.3

GENET

106 ×0.8

117 ×1.0

76 ×0.8

Citations per year, relative to Naibo Hu Naibo Hu (= 1×) peers Arijit Nag

Countries citing papers authored by Naibo Hu

Since Specialization

Citations

This map shows the geographic impact of Naibo Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naibo Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naibo Hu more than expected).

Fields of papers citing papers by Naibo Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naibo Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naibo Hu. The network helps show where Naibo Hu may publish in the future.

Co-authorship network of co-authors of Naibo Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Naibo Hu. A scholar is included among the top collaborators of Naibo Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naibo Hu. Naibo Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Yuan, Yuhui Zhang, Naibo Hu, et al.. (2022). Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors. Thrombosis Research. 212. 38–43. 3 indexed citations

Hu, Naibo, et al.. (2021). Targeted Therapy in CD38 + Acute Myeloid Leukemia. Blood. 138(Supplement 1). 4425–4425. 2 indexed citations

Qin, Tiejun, Zefeng Xu, Huijun Huang, et al.. (2020). [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].. PubMed Central. 41(1). 28–33. 1 indexed citations

Xu, Zefeng, Bing Li, Tiejun Qin, et al.. (2018). Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer Journal. 8(1). 23 indexed citations

Hu, Naibo, Liwei Fang, Tiejun Qin, Zhijian Xiao, & Zefeng Xu. (2018). [Ruxolitinib for chronic neutrophilic leukemia: a case report and literature review].. PubMed. 39(12). 1029–1032. 1 indexed citations

Fang, Liwei, Tiejun Qin, Zefeng Xu, et al.. (2018). [Analysis of Early-Death and Factors Affecting Prognosis of Patients with Acute Promyelocytic Leukemia].. PubMed. 26(1). 52–57. 2 indexed citations

Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2016). TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. PubMed. 3. 50–50. 9 indexed citations

Qu, Shiqiang, Tiejun Qin, Zefeng Xu, et al.. (2016). Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 7(22). 33229–33236. 20 indexed citations

Qin, Tiejun, Zefeng Xu, Yue Zhang, et al.. (2016). [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].. PubMed. 37(2). 94–9. 3 indexed citations

10.

Li, Bing, Jinqin Liu, Shiqiang Qu, et al.. (2016). Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R. Oncotarget. 7(42). 68023–68032. 9 indexed citations

11.

Cui, Yajuan, Hongyan Tong, Xin Du, et al.. (2015). Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Experimental Hematology and Oncology. 4(1). 14–14. 29 indexed citations

12.

Gale, Robert Peter, Wen Cui, Gang Huang, et al.. (2015). A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Experimental Hematology and Oncology. 5(1). 12–12. 18 indexed citations

13.

Wang, Jingya, Tiejun Qin, Zefeng Xu, et al.. (2015). [Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes].. PubMed. 36(11). 942–6. 1 indexed citations

14.

Cui, Wen, Tiejun Qin, Yue Zhang, et al.. (2015). Impact of Megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes. Blood. 126(23). 2876–2876.

15.

Cui, Rui, Robert Peter Gale, Zefeng Xu, et al.. (2014). Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leukemia Research. 38(5). 545–550. 40 indexed citations

16.

Zhang, Hongli, Tiejun Qin, Zefeng Xu, et al.. (2014). [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].. PubMed. 35(1). 18–23. 1 indexed citations

17.

Li, Bing, Chengwen Li, Robert Peter Gale, et al.. (2014). Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. American Journal of Hematology. 89(11). 1043–1046. 8 indexed citations

18.

Wang, Jieyu, Robert Peter Gale, Zefeng Xu, et al.. (2012). TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leukemia Research. 37(3). 305–311. 34 indexed citations

19.

Qin, Tiejun, Zefeng Xu, Liwei Fang, et al.. (2011). [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].. PubMed. 19(5). 1277–82. 2 indexed citations

20.

Hu, Naibo & L.C. Zhang. (2003). A study on the grindability of multidirectional carbon fibre-reinforced plastics. Journal of Materials Processing Technology. 140(1-3). 152–156. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact